
SUPPLEMENT TO: Differential Regulation of ERK and mTOR Signaling Pathways in Failing Human Hearts


# **SUPPLEMENT FIGURES**




Supplemental Figure 1. **Selected clinical and laboratory data**. Scatter plots ± SEM, \* NFN v NFO, † NFO v FND, ‡ NFO v FDM, § NFN v FND, || NFN v FDM, # FND v FDM. Age, weight, height, body surface are (BSA), and body mass index (BMI) are from chart review (A-E). Left ventricular (LV) mass, heart weight, % of LV/Ht wt, heart mass index (HMI, heart weight divided by body surface area), left ventricular mass index (LVMI), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), posterior wall (PW) thickness, and left ventricular ejection fraction (LVEF) are from echocardiography (F-N). Not all calculations were available for the non-failing groups (K-M). Right atrial pressure (RAP), pulmonary artery (PA) systolic, pulmonary artery diastolic (PAD), pulmonary capillary wedge pressure (PCWP), and cardiac index (CI) are calculated from wedge pressures (O-S) and are only available for the failing groups. Plasma creatinine was obtained from chart review (T). Plasma glucose, insulin, fructosamine, and triglycerides (TG) were measured using commercially available assays (U-X).

	NFL (%)	NFO (%)	FND (%)	FDM (%)	PVAL4	PVAL2	PVAL3
Insulin Rx	0 ′	0 ′	0 ′	29 ′	0.0156	0.1429	0.1904
Hypoglycemics Rx	0	0	0	41	0.0005	0.0338	0.1123
Hx of DM	0	0	0	100	<.0001	<.0001	0.0001
Hx of HF	0	0	100	100	<.0001	<.0001	<.0001
Hx of Htn	40	60	86	76	0.0994	0.0314	0.0563
Hx of ChrAfib	0	20	86	41	<.0001	0.0004	0.0003
Hx of VT/VF	0	0	71	47	<.0001	<.0001	<.0001
Hx of MI	0	0	43	47	0.0029	0.0003	0.0011
ASA Rx	20	30	50	82	0.0053	0.0042	0.0107
Lipid Lowering Rx	30	10	64	65	0.0141	0.0036	0.0043
Thyroid med Rx	10	20	0	29	0.1304	1	1
Beta Blocker Rx	0	30	100	94	<.0001	<.0001	<.0001
ACE I Rx	0	20	64	65	0.0008	0.0001	0.0002
Angio II Antag Rx	0	0	29	29	0.0698	0.008	0.0331
Hydralazine Rx	0	0	0	41	0.0005	0.0338	0.1123
Ca Chan Blocker Rx	0	0	14	0	0.142	0.5137	1
Nitrate Rx	0	0	36	29	0.0321	0.0039	0.0178
Dig Rx	0	0	71	41	<.0001	<.0001	0.0001
Diuretic Rx	0	10	93	94	<.0001	<.0001	<.0001
Amiodarone Rx	0	0	50	35	0.0038	0.0006	0.0038
Other Antiarrhythmic Rx	0	0	36	0	0.0011	0.1429	0.1904
Anti Platelet Rx	0	0	29	18	0.1143	0.0338	0.1123
Anticoagulant Rx	0	10	64	35	0.0021	0.0015	0.0033
Milirone Rx	0	0	92	63	<.0001	<.0001	<.0001
Dobutimine Rx	0	0	27	0	0.0266	0.2683	0.7467
Prior AICD	0	0	79	71	<.0001	<.0001	<.0001
Prior Pacemaker	0	10	43	6	0.017	0.1273	0.3215
Prior Bi V Pacer	0	0	79	65	<.0001	<.0001	<.0001
Prior MV Repair	0	0	0	12	0.3271	0.5137	1
Prior CABG	0	0	14	24	0.2105	0.0697	0.2024
Prior Angioplasty	0	0	14	12	0.5741	0.1453	0.4542
Prior Stents	0	0	36	35	0.0221	0.0035	0.01
Prior LVAD	0	0	0	0	n/a	n/a	n/a

Supplemental Table 1. **Medications and Medical and Surgical History**. Prior prescription medications (Rx) and medical (Hx) or surgical history (Prior) were obtained from chart review. Hypertension (htn), chronic atrial fibrillation (ChrAfib), ventricular tachycardia/ventricular fibrillation (VT/VF), myocardial infarction (MI), acetylsalicylic acid (aspirin, ASA), angiotensin converting enzyme inhibitor (ACE I), angiotensin II antagonist (Angio II Antag), Digitonin (Dig), Automatic Implantable Cardioverter Defibrillator (AICD), bi-ventricular (Bi-V) pacer, mitral valve (MV) repair, coronary artery bypass grafting (CABG), left ventricular assist device (LVAD). ANOVA PVAL4 is between all four groups, PVAL2 is between failing and non-failing, and PVAL3 is between NFL and the three groups with cardiac hypertrophy (NFO, FND, FDM).



Supplemental Figure 2. Additional correlations between signaling proteins, cardiac size, function, and glycemia. Absolute protein levels in the four clinical groups (A, E, I, M); ANOVA p<0.05 indicated with \* NFN v NFO, † NFO v FND, ‡ NFO v FDM, § NFN v FND, || NFN v FDM. Correlations of signaling pathways with cardiac size (LVMI, B, F, J, N), function (LVEF, C, G, K, O), and fructosamine (D,H, L, P). Graphs represent all patients in the study with regressions (± 10% CIs), correlation coefficients, and p-values as indicated. Significance indicated by \* for Pearson and † for Spearman.



Supplemental Figure 3. Additional correlations between metabolic proteins, cardiac size, function, and glycemia. Absolute protein levels in the four clinical groups (A, E, I, M); ANOVA p<0.05 indicated with \* NFN v NFO, † NFO v FND, ‡ NFO v FDM, § NFN v FND, || NFN v FDM. Correlations of signaling pathways with cardiac size (LVMI, B, F, J, N), function (LVEF, C, G, K, O), and fructosamine (D,H, L, P). Graphs represent all patients in the study with regressions (± 10% CIs), correlation coefficients, and p-values as indicated. Significance indicated by \* for Pearson and † for Spearman.

Protein	Company	Catalog No.
IRb	Cell Signaling (CS)	3025S
IGFR	0 0 7	3027
PI3K		
p85		4292
p-Akt		9018
Akt		2920
p-Akt1		9018
Akt1		2967
p-Akt2		8599
Akt2		5239
p-ERK1/2		9101
ERK1/2		9107
p-mTOR		2971
mTOR		4517
p-S6		2211
S6		2317
4EBP		9644
p-GSK3b		5558
GSK3b		9832
p-GSK3a/b		9331
p-FOXO3a		9465
p-AS160		8881
AS160		2670
PP2A		2038
р-АМРКа		2531
AMPKa		2793
p-STAT3		9145
STAT3		9139
HK1		2024
HK2		2867
PFKM		8164
GAPDH		2118
PKM2		4053
LDHA		3582
Cytochrome c		4272
GLUT1	Millipore (MP)	07-1401
GLUT4		07-1404
PDE9		ABN32
p-PP2A	Santa Cruz (SC)	271903
OGlcNac	Abcam (ab)	2739
panPDE4		14628
OPA1		42364
NDUFA9		14713
SDHA		14715
UQCRC1		110252
MT-CO1		14705
MT-CO3		110259
ATP5A		14748
H3		1791

Supplemental Table 2. Antibodies utilized for the left ventricular immunoblot studies.

Simple Statistics							
Variable	N	Mean	Std Dev	Sum	Minimum	Maximum	Label
None	96	-0.03386	0.37080	-3.25090	-0.92888	0.96362	Unadjusted Correlation
ВМІ	96	-0.05218	0.41967	-5.00935	-0.80099	0.98379	Partial Correlation Adjusting for BMI
Sex	96	-0.02561	0.43716	-2.45830	-0.86640	0.98261	Partial Correlation Adjusting for Sex
Hx_of_Htn	96	0.0006703	0.40481	0.06435	-0.87327	0.98693	Partial Correlation Adjusting for Hx of Htn
Pacemaker	96	-0.05755	0.40459	-5.52477	-0.81168	0.98561	Partial Correlation Adjusting for Pacemaker
Insulin	96	-0.05671	0.39655	-5.44384	-0.81168	0.98561	Partial Correlation Adjusting for Insulin
PLASMA_INSULIN	96	-0.05297	0.42834	-5.08497	-0.84350	0.99254	Partial Correlation Adjusting for Plasma Insulin
Oral_Hypoglycemics	96	-0.05385	0.39634	-5.16972	-0.81168	0.98561	Partial Correlation Adjusting for Oral Hypoglycemics

Pearson Correlation Coefficients, N = 96 Prob >  r  under H0: Rho=0								
	None	ВМІ	Sex	Hx_of_Htn	Pacemaker	Insulin	PLASMA_INSULIN	Oral_Hypoglycemics
None	1.00000	0.85262	0.85587	0.75833	0.90890	0.92578	0.88714	0.92659
Unadjusted Correlation		<.0001	<.0001	<.0001	<.0001	<.0001	<.0001	<.0001
BMI	0.85262	1.00000	0.90945	0.67892	0.91446	0.93006	0.91293	0.93071
Partial Correlation Adjusting for BMI	<.0001		<.0001	<.0001	<.0001	<.0001	<.0001	<.0001
Sex	0.85587	0.90945	1.00000	0.74700	0.91148	0.92951	0.90675	0.92846
Partial Correlation Adjusting for Sex	<.0001	<.0001		<.0001	<.0001	<.0001	<.0001	<.0001
Hx_of_Htn	0.75833	0.67892	0.74700	1.00000	0.72035	0.72798	0.68784	0.72792
Partial Correlation Adjusting for Hx of Htn	<.0001	<.0001	<.0001		<.0001	<.0001	<.0001	<.0001
Pacemaker Partial Correlation Adjusting for Pacemaker	0.90890 <.0001	0.91446 <.0001	0.91148 <.0001	0.72035 <.0001	1.00000	0.98155 <.0001	0.94475 <.0001	0.98282 <.0001
Insulin	0.92578	0.93006	0.92951	0.72798	0.98155	1.00000	0.96437	0.99804
Partial Correlation Adjusting for Insulin	<.0001	<.0001	<.0001	<.0001	<.0001		<.0001	<.0001
PLASMA_INSULIN Partial Correlation Adjusting for Plasma Insulin	0.88714 <.0001	0.91293 <.0001	0.90675 <.0001	0.68784 <.0001	0.94475 <.0001	0.96437 <.0001	1.00000	0.96311 <.0001
Oral_Hypoglycemics Partial Correlation Adjusting for Oral Hypoglycemics	0.92659 <.0001	0.93071 <.0001	0.92846 <.0001	0.72792 <.0001	0.98282 <.0001	0.99804 <.0001	0.96311 <.0001	1.00000

# Group=NFL

Pearson Correlation Coefficients, N = 24 Prob >  r  under H0: Rho=0				
None Hx_of_Ht				
None Unadjusted Correlation	1.00000	0.96488 <.0001		
Hx_of_Htn Partial Correlation Adjusting for Hx of Htn	0.96488 <.0001	1.00000		

#### Group=FND

Pearson Correlation Coefficients, N = 24 Prob >  r  under H0: Rho=0					
	None	Hx_of_Htn			
None Unadjusted Correlation	1.00000	0.99548 <.0001			
Hx_of_Htn Partial Correlation Adjusting for Hx of Htn	0.99548 <.0001	1.00000			

#### Group=NFO

Pearson Correlation Coefficients, N = 24 Prob >  r  under H0: Rho=0					
None Hx_of_H					
None Unadjusted Correlation	1.00000	0.51477 0.0101			
Hx_of_Htn Partial Correlation Adjusting for Hx of Htn	0.51477 0.0101	1.00000			

## Group=FDM

Pearson Correlation Coefficients, N = 24 Prob >  r  under H0: Rho=0					
None Hx_of_Htm					
None Unadjusted Correlation	1.00000	0.95711 <.0001			
Hx_of_Htn Partial Correlation Adjusting for Hx of Htn	0.95711 <.0001	1.00000			

### SUPPLEMENT FIGURE LEGENDS

Supplemental Figure 1. Selected clinical and laboratory data. Scatter plots ± SEM, \* NFN v NFO, † NFO v FND, ‡ NFO v FDM, § NFN v FND, || NFN v FDM, # FND v FDM. Age, weight, height, body surface are (BSA), and body mass index (BMI) are from chart review (A-E). Left ventricular (LV) mass, heart weight, % of LV/Ht wt, heart mass index (HMI), left ventricular mass index (LVMI), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), posterior wall (PW) thickness, and left ventricular ejection fraction (LVEF) are from echocardiography (F-N). Not all calculations were available for the non-failing groups (K-M). Right atrial pressure (RAP), pulmonary artery (PA) systolic, pulmonary artery diastolic (PAD), pulmonary capillary wedge pressure (PCWP), and cardiac index (CI) are calculated from wedge pressures (O-S) and are only available for the failing groups. Plasma creatinine was obtained from chart review (T). Plasma glucose, insulin, fructosamine, and triglycerides (TG) were measured using commercially available assays (U-X).

Supplemental Table 1. Medications and Medical and Surgical History. Prior prescription medications (Rx) and medical (Hx) or surgical history (Prior) were obtained from chart review. Hypertension (htn), chronic atrial fibrillation (ChrAfib), ventricular tachycardia/ventricular fibrillation (VT/VF), myocardial infarction (MI), acetylsalicylic acid (aspirin, ASA), angiotensin converting enzyme inhibitor (ACE I), angiotensin II antagonist (Angio II Antag), Digitonin (Dig), Automatic Implantable Cardioverter Defibrillator (AICD), bi-ventricular (Bi-V) pacer, mitral valve (MV) repair, coronary artery bypass grafting (CABG), left ventricular assist device (LVAD). ANOVA PVAL4 is between all four groups, PVAL2 is between failing and non-failing, and PVAL3 is between NFL and the three groups with cardiac hypertrophy (NFO, FND, FDM).

Supplemental Figure 2. Additional correlations between signaling proteins, cardiac size, function, and glycemia. Absolute protein levels in the four clinical groups (A, E, I, M); ANOVA p<0.05 indicated with \* NFN v NFO, † NFO v FND, ‡ NFO v FDM, § NFN v FND, || NFN v FDM. Correlations of signaling pathways with cardiac size (LVMI, B, F, J, N), function (LVEF, C, G, K, O), and fructosamine (D,H, L, P). Graphs represent all patients in the study with regressions (± 10% CIs), correlation coefficients, and p-values as indicated. Significance indicated by \* for Pearson and † for Spearman.

Supplemental Figure 3. Additional correlations between metabolic proteins, cardiac size, function, and glycemia. Absolute protein levels in the four clinical groups (A, E, I, M); ANOVA p<0.05 indicated with \* NFN v NFO, † NFO v FND, ‡ NFO v FDM, § NFN v FND, || NFN v FDM. Correlations of signaling pathways with cardiac size (LVMI, B, F, J, N), function (LVEF, C, G, K, O), and fructosamine (D,H, L, P). Graphs represent all patients in the study with regressions (± 10% Cls), correlation coefficients, and p-values as indicated. Significance indicated by \* for Pearson and † for Spearman.

Supplemental Table 2. Antibodies utilized for the left ventricular immunoblot studies.

Supplemental Table 3. Table of Pearson Correlation Coefficients